E-resources
PDF-
Papa, Alfredo; Gasbarrini, Antonio; Tursi, Antonio
The American journal of gastroenterology, 10/2020, Volume: 115, Issue: 10Journal Article
It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19.
